Abstract/Journal Article DZNE-2026-00061

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Multiplex Biomarker Detection in Dried Plasma Spots: finding the best biomarker for remote blood collection

 ;  ;  ;  ;  ;  ;  ;

2025

Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e106925 () [10.1002/alz70856_106925]

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Background: Conventional blood sampling for the testing of Alzheimer's disease (AD) biomarkers depends on stringent, time-sensitive, and temperature-dependent protocols for processing, shipping, and storage. Dry plasma spots (DPS) present a simpler, more scalable alternative for the collection, storage, and transport of blood samples and may offer an alternative sampling when access to blood volume is limited. Notably, neurodegenerative biomarkers such as p-tau, NfL, and GFAP from DPS have demonstrated a strong correlation with paired plasma on other platforms. In this pilot study, we aimed to expand on these findings by exploring a broader panel of central nervous system (CNS) biomarkers using DPS, assessing their potential for reliable and accurate detection. Method: We used the NULISA™ platform to test multiplex detection of a CNS biomarker panel (127 proteins) in DPS and matched plasma, examining plasma–DPS correlations. A discovery cohort (n = 14; mean age 71.1 ± 12.8 years; 8 females [57%]) was selected from the Clinical Neurochemistry Laboratory in Mölndal, Sweden. DPS (Telimmune™ Plasma Separation Card) spiked with venous blood, were analysed with their paired EDTA plasma collected by traditional venipuncture. Pearson correlation was used to compare protein quantification across sample types. Result: We demonstrated several biomarker associations between DPS and plasma with a correlation coefficient >0.99 and p <0.0001 (Figure 1), including APOe4 (r = 0.996), IL6 (r = 0.995), and FABP3 (r = 0.994). Notably, AD-related biomarkers like p-tau181 (r=0.89), p-tau231 (r=0.86), GFAP (r=0.8), NPTX2 (r=0.92), NFL (r=0.95), SMOC1 (r=0.91), and total Tau (r=0.93) all showed strong correlations and p <0.0001. DOPA decarboxylase, relevant for LBD and atypical Parkinsonian disorders, also correlated strongly (r=0.98, p <0.0001). VGF, a biomarker of synaptic plasticity altered in AD and Major Depressive Disorder showed a strong correlation (r = 0.95, p <0.0001). Among 16 interleukins, 11 had r>0.8 (p <0.0003) and 4 had r>0.5 (p <0.05), with IL6 (r=0.995) and IL12 (r=0.994) correlating notably strong (p <0.0001). However, 25% of proteins have a weak correlation coefficient of r<0.5 with plasma. Conclusion: Our findings highlight the potential of DPS as a practical and scalable tool for multiplex biomarker detection. Further research is required to identify and validate optimal AD biomarkers in DPS-based multiplex assays.

Classification:

Contributing Institute(s):
  1. Translational Dementia Research (Bonn) (AG Schneider)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Document types > Presentations > Abstracts
Institute Collections > BN DZNE > BN DZNE-AG Schneider
Documents in Process
Public records
In process

 Record created 2026-01-13, last modified 2026-01-13


Restricted:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)